Understanding how mTORC1 regulates cancer growth and metabolism
Official title: Molecular and structural mechanisms of mTORC1 regulation in cancer
Funded at University of California Berkeley · NIH-11005009 · Data updated 2026-11-12
This study is looking at how a specific protein complex called mTORC1 affects cell growth and metabolism in cancer, especially in kidney cancer, to find better treatment options that are safer for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Berkeley NIH-funded |
| Lab location | 1 site (Berkeley, United States) |
| Project start | January 1, 2024 |
| Project end | December 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $525,631 |
| NIH project number | 5R01CA285366-02 |
| Project ID | NIH-11005009 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include patients with renal cell carcinoma or other cancers associated with mTORC1 dysregulation.
✕Less likely to help
Patients with cancers unrelated to mTORC1 dysregulation may not benefit from this research.
What this research studies
This research investigates the mechanisms by which the mTORC1 complex regulates cell growth and metabolism, particularly in the context of cancer. It focuses on understanding how dysregulation of mTORC1 contributes to various cancers, including renal cell carcinoma. The study employs advanced techniques such as cryo-electron microscopy to explore the structural basis of mTORC1's regulatory pathways, aiming to identify more precise therapeutic targets that could minimize adverse effects associated with current treatments. By targeting specific pathways, the research seeks to improve treatment options for patients with mTORC1-related cancers.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatments for patients with certain types of cancer.
How similar studies have gone: Previous research has shown promising results in targeting mTORC1 pathways, indicating potential for success in this novel approach.
Where this research is happening
-
University of California Berkeley
Berkeley, United States Active
Researchers
- Principal investigator: Hurley, James H — University of California Berkeley
- Study coordinator: Hurley, James H
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.